Interestingly, VPS35D620N has been shown to enhance LRRK2 kinase activity 6-fold in vitro, in CRISPR engineered murine fibroblasts and neutrophils isolated from PD patients carrying VPS35D620N [99]. This evidence concerns the gene LRRK2 and Parkinson disease.